drugset / Trial / NCT02199886
Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection
NaSingle-groupOpen-labelTreatment
Summary
Study to assess the toxicity, pharmacokinetics, biodistribution and imaging characteristics associated with increasing doses of 131I-BIBH 1, to compare the uptake of 131I-BIBH 1 in tumour to that of normal tissue in patients with non-small cell lung cancer and to measure human anti-human antibody (HAHA) concentrations.
Timeline
- Start
- 1998-07
- Primary completion
- 2001-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIBH 1 | Unknown | 0.5 mg/m2 | — |
| Subject | BIBH 1 | Unknown | 2 mg/m2 | — |
| Subject | BIBH 1 | Unknown | 10 mg/m2 | — |
| Subject | BIBH 1 | Unknown | 20 mg/m2 | — |